 |
PDBsum entry 2jkk
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.2
- non-specific protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
|
Plos One
3:e3800
(2008)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation.
|
|
D.Lietha,
M.J.Eck.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase required for cell
migration, proliferation and survival. FAK overexpression has been documented in
diverse human cancers and is associated with a poor clinical outcome. Recently,
a novel bis-anilino pyrimidine inhibitor, TAE226, was reported to efficiently
inhibit FAK signaling, arrest tumor growth and invasion and prolong the life of
mice with glioma or ovarian tumor implants. Here we describe the crystal
structures of the FAK kinase bound to TAE226 and three related bis-anilino
pyrimidine compounds. TAE226 induces a conformation of the N-terminal portion of
the kinase activation loop that is only observed in FAK, but is distinct from
the conformation in both the active and inactive states of the kinase. This
conformation appears to require a glycine immediately N-terminal to the "DFG
motif", which adopts a helical conformation stabilized by interactions with
TAE226. The presence of a glycine residue in this position contributes to the
specificity of TAE226 and related compounds for FAK. Our work highlights the
fact that kinases can access conformational space that is not necessarily
utilized for their native catalytic regulation, and that such conformations can
explain and be exploited for inhibitor specificity.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.A.Lipinski,
and
J.C.Loftus
(2010).
Targeting Pyk2 for therapeutic intervention.
|
| |
Expert Opin Ther Targets,
14,
95.
|
 |
|
|
|
|
 |
A.Fernández,
and
S.Sessel
(2009).
Selective antagonism of anticancer drugs for side-effect removal.
|
| |
Trends Pharmacol Sci,
30,
403-410.
|
 |
|
|
|
|
 |
W.Zhou,
D.Ercan,
L.Chen,
C.H.Yun,
D.Li,
M.Capelletti,
A.B.Cortot,
L.Chirieac,
R.E.Iacob,
R.Padera,
J.R.Engen,
K.K.Wong,
M.J.Eck,
N.S.Gray,
and
P.A.Jänne
(2009).
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
|
| |
Nature,
462,
1070-1074.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |